CA2372053A1 - Compositions and methods for cancer treatment by selectively inhibiting vegf - Google Patents

Compositions and methods for cancer treatment by selectively inhibiting vegf Download PDF

Info

Publication number
CA2372053A1
CA2372053A1 CA002372053A CA2372053A CA2372053A1 CA 2372053 A1 CA2372053 A1 CA 2372053A1 CA 002372053 A CA002372053 A CA 002372053A CA 2372053 A CA2372053 A CA 2372053A CA 2372053 A1 CA2372053 A1 CA 2372053A1
Authority
CA
Canada
Prior art keywords
methods
compositions
vegf
cancer treatment
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002372053A
Other languages
French (fr)
Other versions
CA2372053C (en
Inventor
Philip E. Thorpe
Rolf A. Brekken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
Board Of Regents, The University Of Texas System
Philip E. Thorpe
Rolf A. Brekken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22449437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2372053(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Board Of Regents, The University Of Texas System, Philip E. Thorpe, Rolf A. Brekken filed Critical Board Of Regents, The University Of Texas System
Publication of CA2372053A1 publication Critical patent/CA2372053A1/en
Application granted granted Critical
Publication of CA2372053C publication Critical patent/CA2372053C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y10S530/865—Human
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Abstract

Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors.
The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity.
The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
CA002372053A 1999-04-28 2000-04-28 Compositions and methods for cancer treatment by selectively inhibiting vegf Expired - Fee Related CA2372053C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13143299P 1999-04-28 1999-04-28
US60/131,432 1999-04-28
PCT/US2000/011367 WO2000064946A2 (en) 1999-04-28 2000-04-28 Compositions and methods for cancer treatment by selectively inhibiting vegf

Publications (2)

Publication Number Publication Date
CA2372053A1 true CA2372053A1 (en) 2000-11-02
CA2372053C CA2372053C (en) 2008-09-02

Family

ID=22449437

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002372053A Expired - Fee Related CA2372053C (en) 1999-04-28 2000-04-28 Compositions and methods for cancer treatment by selectively inhibiting vegf

Country Status (17)

Country Link
US (7) US6416758B1 (en)
EP (2) EP1179541B1 (en)
JP (2) JP4926320B2 (en)
KR (1) KR100816572B1 (en)
CN (2) CN101073668A (en)
AT (1) ATE269357T1 (en)
AU (1) AU763954B2 (en)
BR (1) BR0010017A (en)
CA (1) CA2372053C (en)
DE (1) DE60011612T2 (en)
ES (1) ES2223705T3 (en)
HK (1) HK1045700B (en)
IL (1) IL145941A (en)
MX (1) MXPA01010891A (en)
NZ (1) NZ514918A (en)
WO (1) WO2000064946A2 (en)
ZA (2) ZA200108285B (en)

Families Citing this family (521)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
AU2469299A (en) * 1998-01-23 1999-08-09 Cornell Research Foundation Inc. Purified populations of stem cells
US6537520B1 (en) * 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
AU757698C (en) * 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
CA2344653A1 (en) * 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
ATE322909T1 (en) * 1998-12-21 2006-04-15 Ludwig Inst Cancer Res ANTIBODIES TO SHORTENED VEGF-D AND THEIR USES
IT1312077B1 (en) * 1999-04-15 2002-04-04 Univ Degli Studi Milano ANTIANGIOGENIC ACTIVITY POLYPEPTIDES.
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
ES2223705T3 (en) * 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER THROUGH INHIBITION SELECTIVE OF VEGF.
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
JP4776843B2 (en) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド Cancer composition and method using immunoconjugate and chemotherapeutic agent
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP2003511356A (en) * 1999-10-06 2003-03-25 ビーエーエスエフ アクチェンゲゼルシャフト Modulators of cytokine-mediated signaling pathways and integrin αvβ3 receptor antagonists for combination therapy
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US7125542B2 (en) * 2000-02-10 2006-10-24 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
AU2001242432B2 (en) * 2000-02-24 2007-11-08 Eidgenossische Technische Hochschule Zurich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2404528A1 (en) 2000-03-31 2001-10-04 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
FR2813606B1 (en) * 2000-09-01 2004-04-30 Inst Nat Sante Rech Med TRUNKED PROTEIN BARD1, AND ITS DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
US8314060B2 (en) * 2000-09-05 2012-11-20 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
IL154696A (en) * 2000-09-05 2008-11-03 Biosight Ltd Peptide conjugated anti-cancer prodrugs
CN1246333C (en) * 2000-09-07 2006-03-22 舍林股份公司 Recepter in the EDb Fibronection domain
US20020091082A1 (en) * 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
JP3712393B2 (en) * 2000-10-20 2005-11-02 エーザイ株式会社 Nitrogen-containing aromatic ring derivatives
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
AU2002327164A1 (en) * 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
CN1494553A (en) * 2001-01-29 2004-05-05 IDECҩ�﹫˾ Modified antibodies and method of use
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US7601825B2 (en) 2001-03-05 2009-10-13 Agensys, Inc. Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer
US6924358B2 (en) * 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
CN100589845C (en) * 2001-03-07 2010-02-17 麦康公司 Anti-neovasculature preparations for cancer
US20030068319A1 (en) * 2001-03-23 2003-04-10 Menashe Bar-Eli Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-IL8 and anti-MUC18 in diverse types of tumors
WO2002079254A1 (en) * 2001-03-29 2002-10-10 Janoff Edward N Human monoclonal antibodies against capsular polysaccharides of streptococcus pneumoniae
WO2002081649A2 (en) 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
US20030191073A1 (en) * 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2002083850A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
KR20030093316A (en) 2001-04-13 2003-12-06 휴먼 게놈 사이언시즈, 인코포레이티드 Vascular endothelial growth factor 2
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
EP1401875A4 (en) * 2001-05-04 2005-01-26 Univ Utah Res Found Hyaluronic acid containing bioconjugates : targeted delivery of anti-cancer drugs to cancer cells
US7456146B2 (en) * 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
EP1390069A1 (en) * 2001-05-30 2004-02-25 Cornell Research Foundation, Inc. Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
JP4619651B2 (en) * 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド Modified antibodies against prostate-specific membrane antigen and uses thereof
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP2005501011A (en) * 2001-06-08 2005-01-13 ユタ ベンチャー ザ セカンド リミテッド パートナーシップ Tissue-specific inner membrane protein
EP1515707A4 (en) * 2001-06-20 2005-10-19 Imclone Systems Inc Method of treating atherosclerosis and other inflammatory diseases
EP1423428B2 (en) * 2001-06-20 2012-11-14 Fibron Ltd. Antibodies that block fgfr3 activation, methods of screening for and uses thereof
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
ATE477280T1 (en) * 2001-06-28 2010-08-15 Domantis Ltd DOUBLE-SPECIFIC LIGAND AND USE THEREOF
WO2004003019A2 (en) * 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2003006059A1 (en) * 2001-07-13 2003-01-23 Imclone Systems Incorporated Vegfr-1 antibodies to treat breast cancer
US7662374B2 (en) * 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
WO2003014326A2 (en) * 2001-08-10 2003-02-20 Imclone Systems Incorporated Isolation and mobilization of stem cells expressing vegfr-1
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP2287186B1 (en) * 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
WO2003024388A2 (en) * 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
US20030129193A1 (en) * 2001-09-27 2003-07-10 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coaguligand treatment
BR0213303A (en) * 2001-10-15 2005-06-07 Immunomedics Inc Direct Bleach Binding Proteins
WO2003040340A2 (en) * 2001-11-07 2003-05-15 Agensys, Inc. Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
WO2003047633A2 (en) * 2001-12-04 2003-06-12 Nanospectra Biosciences, Inc. Treatment of angiogenesis disorders using targeted nanoparticles
JP2005516965A (en) * 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド Method using anti-MUC18 antibody
US20030194421A1 (en) * 2001-12-28 2003-10-16 Angiotech Pharmaceuticals, Inc. Treatment of uveitis
DE60226499D1 (en) 2001-12-28 2008-06-19 Amgen Fremont Inc USE OF ANTIBODIES TO THE MUC18 ANTIGEN
AU2002367318B2 (en) * 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2239274A1 (en) * 2002-01-03 2010-10-13 Bayer Schering Pharma AG New methods for diagnosis and treatment of tumours
JP4242590B2 (en) 2002-01-11 2009-03-25 俊一 塩澤 Disease susceptibility genes for rheumatoid arthritis and use thereof
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
CA2472578A1 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
WO2003062404A1 (en) * 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US20050042632A1 (en) * 2002-02-13 2005-02-24 Sirna Therapeutics, Inc. Antibodies having specificity for nucleic acids
US7071311B2 (en) * 2002-02-13 2006-07-04 Sirna Therapeutics, Inc. Antibodies having specificity for 2′-C-allyl nucleic acids
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20030223994A1 (en) * 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US8491896B2 (en) * 2002-06-14 2013-07-23 Immunomedics, Inc. Anti-pancreatic cancer antibodies
ES2362931T3 (en) * 2002-03-04 2011-07-15 Imclone Llc SPECIFIC HUMAN ANTIBODIES AGAINST KDR AND USES OF THE SAME.
SG108837A1 (en) * 2002-03-11 2005-02-28 Pi Eta Consulting Co Pte Ltd An enterprise knowledge and information acquisition, management and communications system with intelligent user interfaces
AU2003218194A1 (en) * 2002-03-15 2003-09-29 Attenuon, Llc Cell surface tropomyosin as a target of angiogenesis inhibition
US20060002940A1 (en) * 2002-03-15 2006-01-05 Jennifer Stevenson Method of immunotherapy
US20070178065A1 (en) * 2002-05-03 2007-08-02 Lattime Edmund C Neutralizing factors as vaccine adjuvants
US20050169883A1 (en) * 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
DE60326950D1 (en) * 2002-05-15 2009-05-14 Janssen Pharmaceutica Nv N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLE AS PDGF RECEPTORENHERMMER
JP4405916B2 (en) 2002-05-23 2010-01-27 トラスティース・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア FAS peptidomimetics and uses thereof
AU2003241024A1 (en) * 2002-05-29 2003-12-19 Immunomedics, Inc. Methods and compositions for radioimmunotherapy of brain and cns tumors
JP4511108B2 (en) * 2002-05-31 2010-07-28 オンコリクス インコーポレイテッド Human prolactin antagonist-angiogenesis inhibitor fusion protein
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
CN1675245B (en) * 2002-06-14 2011-01-12 免疫医疗公司 Monoclonal antibody hPAM4
US9599619B2 (en) 2002-06-14 2017-03-21 Immunomedics, Inc. Anti-pancreatic cancer antibodies
WO2003106497A1 (en) * 2002-06-14 2003-12-24 Immunomedics, Inc. Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer
US8821868B2 (en) 2002-06-14 2014-09-02 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1537146B9 (en) 2002-07-15 2011-07-06 Board Of Regents, The University Of Texas System Antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections
EP1546121B1 (en) 2002-07-18 2012-08-29 Janssen Pharmaceutica NV Substituted triazine kinase inhibitors
NZ520321A (en) * 2002-07-19 2005-03-24 Auckland Uniservices Ltd Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal
SI2357006T1 (en) * 2002-07-31 2016-01-29 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
PL219749B1 (en) * 2002-08-16 2015-07-31 Janssen Pharmaceutica Nv Piperidinyl compounds that selectively bind integrins
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
ES2533963T3 (en) * 2002-10-10 2015-04-16 Merck Patent Gmbh Pharmaceutical compositions targeting Erb-B1 receptors
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
PT1572748E (en) * 2002-12-17 2010-09-28 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
EP1578801A2 (en) * 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20050026826A1 (en) * 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides
US20060039858A1 (en) * 2003-02-11 2006-02-23 Ekaterina Dadachova Radiolabeled antibodies and peptides for treatment of tumors
US7402385B2 (en) * 2003-02-11 2008-07-22 Albert Einstein College Of Medicine Of Yeshiva University Radiolabeled antibodies for treatment of tumors
US20080025989A1 (en) * 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7759468B1 (en) * 2003-03-05 2010-07-20 University Of Kentucky Research Foundation Bioactive peptide-based probes
US20060231107A1 (en) * 2003-03-07 2006-10-19 Glickman Randolph D Antibody-targeted photodynamic therapy
JPWO2004080462A1 (en) * 2003-03-10 2006-06-08 エーザイ株式会社 c-Kit kinase inhibitor
PT1608685E (en) * 2003-03-28 2007-05-31 Regeneron Pharma Vegf antagonists for the treatment of diabetes
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
JP4703567B2 (en) * 2003-05-23 2011-06-15 ジェネンテック， インコーポレイテッド Compositions and methods for diagnosis and treatment of tumors of glial cell origin
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
BRPI0411200A (en) * 2003-05-30 2006-07-18 Genentech Inc cancer treatment method, human patient treatment methods, industrialized article and cancer treatment kit
US7605235B2 (en) * 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
US20050008649A1 (en) * 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
WO2005000223A2 (en) * 2003-06-04 2005-01-06 Children's Medical Center Corporation Method of treating retinopathies and disorders associated with blood vessel loss
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
EP2338506A3 (en) * 2003-06-17 2011-10-12 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
US7591953B2 (en) 2003-06-25 2009-09-22 Peregrine Pharmaceuticals, Inc. Methods and apparatus for continuous large-scale radiolabeling of proteins
CN1816351A (en) * 2003-06-27 2006-08-09 艾伯吉尼斯公司 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
KR101581040B1 (en) * 2003-06-27 2015-12-30 암젠 프레몬트 인코포레이티드 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2005000086A2 (en) * 2003-06-30 2005-01-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS
AU2004253630B2 (en) 2003-07-02 2010-11-25 Innate Pharma S.A.S. Methods for the production and cytotoxicity evaluation of KIR2DL NK-receptor antibodies
US20090191213A9 (en) * 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
AR046510A1 (en) 2003-07-25 2005-12-14 Regeneron Pharma COMPOSITION OF A VEGF ANTAGONIST AND AN ANTI-PROLIFERATIVE AGENT
CA2533878A1 (en) * 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
AP2012006644A0 (en) * 2003-08-01 2012-12-31 Genentech Inc Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
AU2012201667B2 (en) * 2003-08-01 2014-11-27 Genentech, Inc. Anti-VEGF antibodies
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
WO2005016369A1 (en) * 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist in combination with radiation therapy
EP1651663B1 (en) * 2003-08-08 2017-05-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US7547518B2 (en) * 2003-08-19 2009-06-16 Becton, Dickinson And Company Method of screening endothelial cells for angiogenic capability
PT1660057E (en) * 2003-08-27 2012-08-02 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
WO2005074417A2 (en) * 2003-09-03 2005-08-18 Salk Institute For Biological Studies Multiple antigen detection assays and reagents
CA2543888C (en) 2003-11-06 2016-01-19 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US7683172B2 (en) * 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
WO2005047319A2 (en) * 2003-11-12 2005-05-26 The University Of Georgia Research Foundation, Inc. Dna sequence and expressed recombinant glycoproteins related to feline thyrotropin
EP1682516A2 (en) * 2003-11-13 2006-07-26 Janssen Pharmaceutica N.V. Immobilized n-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets
WO2005048938A2 (en) * 2003-11-13 2005-06-02 California Pacific Medical Center Anti-pecam therapy for metastasis suppression
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
WO2005056764A2 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
US7799327B2 (en) * 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US20090155266A1 (en) * 2004-01-16 2009-06-18 Yale University Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
WO2005072340A2 (en) * 2004-01-27 2005-08-11 Compugen Ltd. Novel polynucleotides encoding polypeptides and methods using same
US20110020273A1 (en) * 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
AU2005219413A1 (en) * 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
US20050214280A1 (en) * 2004-03-02 2005-09-29 Ludwig Institute For Cancer Research Method for inhibiting tumor formation and growth
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
ATE507240T1 (en) * 2004-03-05 2011-05-15 Vegenics Pty Ltd MATERIALS AND METHODS FOR GROWTH FACTOR BINDING CONSTRUCTS
EP1723422A2 (en) * 2004-03-05 2006-11-22 The Scripps Research Institute High throughput glycan microarrays
US7745230B2 (en) * 2004-03-10 2010-06-29 Creighton University Estrogen receptors and methods of use
AU2012265582B2 (en) * 2004-03-26 2015-04-16 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
JP2008505853A (en) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド Non-natural ribonuclease complex as a cytotoxic agent
PT1742966E (en) 2004-04-22 2014-02-05 Agensys Inc Antibodies and molecules derived therefrom that bind to steap-1 proteins
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
CN1304427C (en) * 2004-06-08 2007-03-14 成都康弘生物科技有限公司 Angiogenesis inhibiting fusion protein and its use
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
WO2006009786A2 (en) * 2004-06-18 2006-01-26 Elmaleh David R Intravascular imaging device and uses thereof
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
CA2601417C (en) * 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
JP4991532B2 (en) * 2004-07-02 2012-08-01 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ Alpha helix mimic
CN1997386B (en) * 2004-07-30 2012-05-30 瑞泽恩制药公司 Methods of treating type I diabetes by blocking VEGF-mediated activity
DK2299275T3 (en) 2004-07-30 2018-05-07 Adeza Biomedical Corp Classification of oncofetal fetronectin level for pregnancy-related indications
EP2412728B1 (en) 2004-08-03 2015-01-07 Innate Pharma Therapeutic compositions against cancer targeting 4IG-B7-H3
US20070003943A1 (en) * 2004-08-09 2007-01-04 Northwestern University Tumor angiogenesis inhibitor alpha 1-antitrypsin
CN1316249C (en) * 2004-08-25 2007-05-16 北京健平九星生物医药科技有限公司 Enzyme-linked assay kit and producing process thereof
WO2006024092A1 (en) * 2004-08-31 2006-03-09 Newsouth Innovations Pty Limited Vegf inhibition
SV2007002227A (en) * 2004-09-10 2007-03-20 Wyeth Corp ANTI-5T4 HUMANIZED AND CONJUGATED ANTIBODIES ANTI-5T4 ANTIBODY / CALICHEAMICINA REF. 040000-0317637
US8772269B2 (en) * 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
EP1799812A4 (en) * 2004-09-16 2009-09-09 Gamida Cell Ltd Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
WO2006030826A1 (en) * 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. Medicinal composition
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
BRPI0517551A (en) * 2004-10-04 2008-10-14 Cellgate Inc polyamine analogues as therapeutic agents for eye diseases
AU2005308539A1 (en) * 2004-10-06 2006-06-01 Tiltan Pharma Ltd Method and composition for enhancing anti-angiogenic therapy
US8337838B2 (en) * 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
JP5222559B2 (en) * 2004-10-15 2013-06-26 シアトル ジェネティックス， インコーポレイテッド Anti-CD70 antibodies and uses thereof for the treatment and prevention of cancer and immune disorders
US7641903B2 (en) * 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
PT1802334E (en) * 2004-10-21 2012-11-28 Genentech Inc Method for treating intraocular neovascular diseases
ES2325344B1 (en) * 2004-11-02 2010-06-09 Univ Madrid Autonoma MULTIFUNCTIONAL AND MULTIVALENT ANGIOGENESIS INHIBITORS.
US7595149B1 (en) 2004-11-08 2009-09-29 University Of Kentucky Research Foundation Methods for cancer detection
SI1819358T1 (en) 2004-11-18 2014-10-30 Imclone Llc Antibodies against vascular endothelial growth factor receptor-1
WO2006068758A2 (en) * 2004-11-19 2006-06-29 The Scripps Research Institute Detection, prevention and treatment of breast cancer
MX2007007165A (en) * 2004-12-17 2007-08-14 Genentech Inc Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy.
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
PT2727583T (en) 2004-12-22 2021-12-27 Nitto Denko Corp Drug carrier and drug carrier kit for inhibiting fibrosis
EP1831258B2 (en) 2004-12-28 2023-06-07 Innate Pharma S.A. Monoclonal antibodies against nkg2a
WO2006071983A2 (en) 2004-12-29 2006-07-06 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
CN101146550B (en) * 2004-12-29 2013-04-17 曼康公司 Use of immunogenicity composition in preparing kit for initiating and enhancing immune responses
EP1835937B1 (en) 2005-01-06 2012-04-11 Novo Nordisk A/S Compositions and methods for treating viral infection
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
US8222376B2 (en) 2005-01-06 2012-07-17 Novo Nordisk A/S KIR-binding agents and methods of use thereof
US20080248030A1 (en) * 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
NZ599464A (en) 2005-02-03 2014-03-28 Topotarget Uk Ltd Combination therapies using hdac inhibitors
DK1871805T3 (en) 2005-02-07 2019-12-02 Roche Glycart Ag ANTI-BINDING MOLECULES BINDING EGFR, VECTORS CODING THEREOF, AND APPLICATIONS THEREOF
US20060188508A1 (en) * 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
WO2006094026A1 (en) * 2005-03-02 2006-09-08 Nascent Pharmaceuticals, Inc. Pharmaceutically acceptable carrier for ophthalmic compositions
AU2006223314A1 (en) * 2005-03-11 2006-09-21 Regeneron Pharmaceuticals, Inc. Treating anemia by inhibition of VEGF
CA2598711C (en) 2005-03-25 2018-05-29 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
AU2006230563B8 (en) * 2005-03-31 2010-06-17 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
US20060222595A1 (en) * 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
US8350009B2 (en) * 2005-03-31 2013-01-08 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
EP1712241A1 (en) * 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
EP1871418B1 (en) 2005-04-19 2014-03-19 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
EP2494969B1 (en) 2005-05-13 2015-03-25 TopoTarget UK Limited Pharmaceutical formulations of HDAC inhibitors
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
US7767710B2 (en) 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
WO2006130673A1 (en) * 2005-05-31 2006-12-07 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
US7825244B2 (en) * 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20060281768A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
US8071768B2 (en) * 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
CN101198620A (en) 2005-06-17 2008-06-11 曼康公司 Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
EP1748050A1 (en) * 2005-07-28 2007-01-31 Rijksuniversiteit Groningen Targeting-enhanced activation of galectins
EP1925941B1 (en) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (en) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
DE602006020881D1 (en) 2005-08-15 2011-05-05 Vegenics Pty Ltd ENEN FEATURES
AU2006285673B2 (en) * 2005-09-01 2010-12-02 Eisai R&D Management Co., Ltd. Method for preparation of pharmaceutical composition having improved disintegratability
DK1937815T3 (en) * 2005-09-13 2015-08-03 Nat Res Council Canada Methods and compositions for the modulation of tumor cell activity
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
US20070071756A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an agent to ameliorate inflammation
EA016186B1 (en) * 2005-09-26 2012-03-30 Медарекс, Инк. Human monoclonal antibodies to cd70 and use thereof
CA2623109C (en) 2005-10-14 2019-02-19 Innate Pharma Nk cell-depleting antibodies for treating immunoproliferative disorders
US7795279B2 (en) 2005-10-18 2010-09-14 Janssen Pharmaceutica Nv Method of inhibiting FLT3 kinase
CN101534865A (en) * 2005-10-19 2009-09-16 Ibc药品公司 Methods and compositions for generating bioactive assemblies of increased complexity and uses
WO2007050415A2 (en) * 2005-10-21 2007-05-03 Medivas, Llc Poly(ester urea) polymers and methods of use
US20090291437A1 (en) * 2005-11-02 2009-11-26 O'brien Sean Methods for targeting quadruplex sequences
EP1949902B1 (en) 2005-11-07 2012-06-27 Eisai R&D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
US8041428B2 (en) 2006-02-10 2011-10-18 Electrocore Llc Electrical stimulation treatment of hypotension
US8812112B2 (en) * 2005-11-10 2014-08-19 ElectroCore, LLC Electrical treatment of bronchial constriction
US9037247B2 (en) 2005-11-10 2015-05-19 ElectroCore, LLC Non-invasive treatment of bronchial constriction
CN101674862A (en) * 2005-11-10 2010-03-17 电子核心公司 Electrical stimulation treatment of bronchial constriction
US20110125203A1 (en) * 2009-03-20 2011-05-26 ElectroCore, LLC. Magnetic Stimulation Devices and Methods of Therapy
CA2627923C (en) * 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
AU2006321364B2 (en) * 2005-12-01 2011-11-10 Domantis Limited Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
CA2630839C (en) † 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
RS55630B1 (en) * 2005-12-21 2017-06-30 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
EP1978985A2 (en) * 2005-12-23 2008-10-15 Board Of Regents Of The University Of Texas System Anti-hyperproliferative therapies targeting hdgf
US20090317475A1 (en) * 2006-01-03 2009-12-24 Beardsley Robert A Combination antitumor therapies
WO2007129223A2 (en) * 2006-01-23 2007-11-15 Ad Group Systems and methods for distributing emergency messages
US20070175313A1 (en) * 2006-01-31 2007-08-02 Kevin Vandervliet MP3 player holder assembly
EP1984065B1 (en) * 2006-02-10 2012-08-22 Electrocore, Inc. Electrical stimulation treatment of hypotension
AU2006337679A1 (en) * 2006-02-10 2007-08-16 Electrocore, Inc. Methods and apparatus for treating anaphylaxis using electrical modulation
US20070202593A1 (en) * 2006-02-27 2007-08-30 Research Development Foundation Cell-Targeted IKB and Methods for the Use Thereof
ES2363891T3 (en) * 2006-03-20 2011-08-18 The Regents Of The University Of California ANTIBODIES AGAINST THE ANTIGEN OF TRONCAL CELLS OF THE PROSTATE (PSCA) GENETICALLY MODIFIED FOR ADDRESSING TO CANCER.
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
TWI390034B (en) 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
SMP200800060B (en) * 2006-04-07 2009-07-14 Procter & Gamble Antibodies that bind the human protein tyrosine phosphatase beta (hptbeta) and their uses
US20100241188A1 (en) * 2009-03-20 2010-09-23 Electrocore, Inc. Percutaneous Electrical Treatment Of Tissue
SI2021335T1 (en) * 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Heterocyclic compounds as inhibitors of c-fms kinase
ES2564781T3 (en) 2006-04-20 2016-03-29 Janssen Pharmaceutica, N.V. C-fms kinase inhibitors
WO2007124369A2 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Method of inhibiting c kit kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
US20070253960A1 (en) * 2006-04-28 2007-11-01 Josee Roy Pharmaceutical removal of vascular extensions from a degenerating disc
WO2007128526A2 (en) * 2006-05-04 2007-11-15 Fovea Pharmaceuticals Sa Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
US20070265170A1 (en) * 2006-05-15 2007-11-15 Ola Blixt Detection, prevention and treatment of ovarian cancer
CN101443009A (en) * 2006-05-18 2009-05-27 卫材R&D管理有限公司 Antitumor agent for thyroid cancer
AU2007254167B2 (en) * 2006-05-19 2012-11-15 Technion Research And Development Foundation Ltd. Fusion proteins, uses thereof and processes for producing same
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US8101721B2 (en) * 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
EP2040751A2 (en) * 2006-06-15 2009-04-01 Biogen Idec MA Inc. Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents
DK2944306T3 (en) 2006-06-16 2021-03-08 Regeneron Pharma Suitable VEGF antagonist formulations for intravitreal administration
JP2009541333A (en) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド Modified ribonuclease
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US20090203693A1 (en) * 2006-06-29 2009-08-13 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
WO2008036449A2 (en) * 2006-06-29 2008-03-27 The Regents Of The University Of California Chemical antibodies for immunotherapy and imaging
EP2049151A4 (en) 2006-07-17 2010-03-24 Quintessence Biosciences Inc Methods and compositions for the treatment of cancer
BRPI0714981A2 (en) * 2006-07-28 2013-08-13 Sanofi Aventis A method of making the same comprising an inhibitor that inhibits the activity of a complex iii protein, a vehicle and a member of the tumor necrosis factor superfamily, a method for conducting an assay to determine whether a compound is an inhibitor. of tnf suppression activity of a complex iii protein and use of a compound
AR062223A1 (en) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE
WO2008026748A1 (en) * 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US20080070855A1 (en) * 2006-09-20 2008-03-20 James Pitzer Gills Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes
BRPI0717431A2 (en) * 2006-09-29 2013-11-12 Oncomed Pharm Inc CANCER DIAGNOSTIC AND TREATMENT COMPOSITIONS AND METHODS
EA200900562A1 (en) * 2006-10-17 2009-10-30 Дайэкс Корп. METHOD OF TREATING DISORDERS ASSOCIATED WITH ANGIOGENESIS
US8975374B2 (en) * 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
EP2093237B1 (en) 2006-10-20 2015-12-30 Chugai Seiyaku Kabushiki Kaisha Anti-cancer agent comprising anti-hb-egf antibody as active ingredient
AU2007311957A1 (en) * 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
PL2087002T3 (en) * 2006-10-27 2015-02-27 Lpath Inc Compositions and methods for binding sphingosine-1-phosphate
WO2008052187A2 (en) * 2006-10-27 2008-05-02 Genentech. Inc. Antibodies and immunoconjugates and uses therefor
CN101687031B (en) * 2006-10-27 2014-05-14 勒帕斯公司 Compositions and methods for treating ocular diseases and conditions
US20100029674A1 (en) 2006-11-17 2010-02-04 Innate Pharma, S.A. Methods of Using Phosphoantigen for the Treatment of Cancer
JP5537946B2 (en) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Targeted therapeutic agents based on modified proteins for tyrosine kinase receptors including IGF-IR
WO2008064336A2 (en) 2006-11-22 2008-05-29 Inivitrogen Corporation Autoimmune disease biomarkers
NZ578354A (en) * 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
AU2007333735A1 (en) * 2006-12-19 2008-06-26 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
WO2008074853A1 (en) * 2006-12-21 2008-06-26 Novartis Ag Ophthalmic rebamipide solution
JP5618172B2 (en) * 2007-01-05 2014-11-05 国立大学法人東京大学 Diagnosis and treatment of cancer using anti-PRG-3 antibody
WO2008089070A2 (en) * 2007-01-12 2008-07-24 Dyax Corp. Combination therapy for the treatment of cancer
EP2119707B1 (en) * 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
US7816390B2 (en) * 2007-01-31 2010-10-19 Janssen Pharmaceutica Nv N-substituted tricyclic 3-aminopyrazoles as anti-mitotic tubulin polymerization inhibitors
US20100144599A1 (en) * 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
WO2008093246A2 (en) * 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
TWI407971B (en) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
US20080286337A1 (en) * 2007-05-15 2008-11-20 Boston Foundation For Sight Method of treating a disease in an eye using a scleral lens
CA2683801A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
KR100883430B1 (en) 2007-06-13 2009-02-12 한국생명공학연구원 Human Monoclonal Antibody Neutralizing Vesicular Endothelial Growth Factor Receptor and Use Thereof
PE20090368A1 (en) * 2007-06-19 2009-04-28 Boehringer Ingelheim Int ANTI-IGF ANTIBODIES
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
US20090047689A1 (en) * 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
JP5548123B2 (en) * 2007-06-21 2014-07-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Polymorphs and Hydration of 6- {Difluoro [6- (1-methyl-1H-pyrazol-4-yl) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] methyl} quinoline Form, salt, and production method
US8334239B2 (en) 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists
DK2474557T3 (en) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
ES2528922T3 (en) 2007-07-16 2015-02-13 Genentech, Inc. Humanized and immunoconjugate anti-CD79b antibodies and methods of use
JP2010538972A (en) * 2007-08-20 2010-12-16 ブリストル−マイヤーズ スクイブ カンパニー Use of a VEGFR-2 inhibitor for the treatment of metastatic cancer
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2009036368A2 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
EP2203421B1 (en) * 2007-09-25 2014-05-07 TopoTarget UK Limited Methods of synthesis of certain n-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide compounds
US20090163440A1 (en) * 2007-09-26 2009-06-25 Waddell David D Ion-Channel Regulator Compositions and Methods of Using Same
EP2740490A1 (en) * 2007-10-03 2014-06-11 Cornell University Treatment of proliferative disorders using antibodies to PSMA
US8697062B2 (en) * 2007-10-08 2014-04-15 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapeutics
JO3240B1 (en) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv Inhibitors of c-fms Kinase
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
WO2009061830A1 (en) * 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
WO2009062174A1 (en) * 2007-11-08 2009-05-14 University Of Utah Research Foundation Use of angiogenesis antagonists in conditions of abnormal venous proliferation
AU2013205269B2 (en) * 2007-11-09 2016-05-19 Affitech Research As Anti-VEGF antibody compositions and methods
MX2010005104A (en) * 2007-11-09 2010-08-04 Peregrine Pharmaceuticals Inc Anti-vegf antibody compositions and methods.
EP2218712B1 (en) 2007-11-09 2015-07-01 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
ES2369717T3 (en) * 2007-11-30 2011-12-05 F. Hoffmann-La Roche Ag STABILIZATION OF CONJUGATES UNDERSTANDING A TIOUREA CONNECTOR MOLECULE.
TWI580694B (en) * 2007-11-30 2017-05-01 建南德克公司 Anti-vegf antibodies
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
UA100255C2 (en) * 2007-12-28 2012-12-10 Біоінвент Інтернешенл Аб Pharmaceutical composition
US9358307B2 (en) * 2008-01-25 2016-06-07 Gavish-Galilee Bio Applications Ltd. Targeting of innate immune response to tumor site
CN102036962B (en) * 2008-01-29 2013-08-07 卫材R&D管理有限公司 Combined use of angiogenesis inhibitor and taxane
AU2009210636B2 (en) 2008-01-31 2014-08-28 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
DK2262493T3 (en) * 2008-03-07 2015-04-27 Onxeo Dk Branch Of Onxeo S A France METHODS OF TREATMENT WITH prolonged continuous infusion of Belinostat
DK2254571T3 (en) 2008-03-18 2015-09-28 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and the chemotherapeutic agents and methods of using
WO2009120178A1 (en) * 2008-03-26 2009-10-01 Epitomics, Inc. Anti-vegf antibody
AU2014202474B2 (en) * 2008-03-26 2016-07-28 Epitomics, Inc. Anti-VEGF antibody
KR100998569B1 (en) * 2008-03-31 2010-12-07 한국원자력연구원 A radioimmunoconjugate for diagnosis and treatment of cancer or metastasis and development of cancer or cancer metastasis inhibitor using thereof
WO2009125394A1 (en) * 2008-04-09 2009-10-15 Technion Research & Development Foundation Ltd. Anti human immunodeficiency antibodies and uses thereof
CN102083615B (en) * 2008-04-10 2014-08-13 战略系统有限公司 System and method for three dimensional model printing
JP5624535B2 (en) 2008-05-02 2014-11-12 シアトル ジェネティクス，インコーポレーテッド Methods and compositions for preparing antibodies and antibody derivatives having low core fucosylation
CA2723277A1 (en) 2008-05-02 2009-11-05 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
ES2338400B1 (en) * 2008-05-06 2011-09-14 David Benet Ferrus SET OF ANTIANGIOGEN MOLECULES AND ITS USE.
US8082730B2 (en) * 2008-05-20 2011-12-27 Caterpillar Inc. Engine system having particulate reduction device and method
WO2009142773A2 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US20090298088A1 (en) * 2008-05-30 2009-12-03 Belyaev Alexander S Cleavable catalytic binding and detection system
HUE032894T2 (en) 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit Stable and soluble antibodies inhibiting vegf
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
CN102227443B (en) 2008-10-01 2014-05-14 昆特森斯生物科学公司 Therapeutic ribonucleases
US9434610B2 (en) * 2008-10-07 2016-09-06 Rexahn Pharmaceuticals, Inc. HPMA—docetaxel conjugates and uses therefore
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
DK3290052T3 (en) 2008-11-07 2020-02-03 Galaxy Biotech Llc MONOCLONAL ANTIBODIES AGAINST FIBROBLAST GROWTH FACTOR RECEPTOR 2
PA8849001A1 (en) 2008-11-21 2010-06-28 Lilly Co Eli C-MET ANTIBODIES
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
KR101093717B1 (en) 2008-11-26 2011-12-19 한국생명공학연구원 VEGF?specific human antibody
EA029178B1 (en) 2008-12-12 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Anti-insulin-like growth factor antibodies, dna molecule, vector, host cell provided for producing this antibody, method for producing same and use
RU2636046C2 (en) * 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Modified antibodies composition, methods of production and application
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
WO2010091234A2 (en) 2009-02-06 2010-08-12 The General Hospital Corporation Methods of treating vascular lesions
DK3903829T3 (en) 2009-02-13 2023-06-26 Immunomedics Inc IMMUNE CONJUGATES WITH AN INTRACELLULAR CLEAVABLE BOND
ES2712732T3 (en) * 2009-02-17 2019-05-14 Cornell Res Foundation Inc Methods and kits for the diagnosis of cancer and the prediction of therapeutic value
EP2398494A4 (en) 2009-02-23 2015-10-28 Cytomx Therapeutics Inc Proproteins and methods of use thereof
KR101224468B1 (en) 2009-05-20 2013-01-23 주식회사 파멥신 Bispecific antibody having a novel form and use thereof
US20120135064A1 (en) * 2009-05-27 2012-05-31 Northeastern University Conjugated nanodelivery vehicles
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
BRPI1006897A2 (en) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compounds, compositions and methods for preventing cancer cell metastasis.
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
CN102002104A (en) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 Anti-VEGF monoclonal antibody and medicinal composition containing same
US8178307B2 (en) * 2009-09-02 2012-05-15 National Tsing Hua University Methods and compositions for detection of lethal cell and uses thereof
WO2011028642A1 (en) 2009-09-04 2011-03-10 University Of Louisville Research Foundation, Inc. Genetic determinants of prostate cancer risk
EP2293071A1 (en) * 2009-09-07 2011-03-09 Universität Zu Köln Biomarker for colorectal cancer
IN2012DN01663A (en) 2009-09-16 2015-06-05 Immunomedics Inc
AU2010306917B2 (en) 2009-10-13 2014-11-27 Rexahn Pharmaceuticals, Inc. Polymeric systems for the delivery of anticancer agents
EP2488204B1 (en) 2009-10-16 2016-04-06 Oncomed Pharmaceuticals, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
EP2504363B1 (en) 2009-11-24 2019-05-08 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
EP3135302A1 (en) 2009-12-02 2017-03-01 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
CA2787753A1 (en) * 2010-01-22 2011-07-28 Immunomedics, Inc. Detection of early-stage pancreatic adenocarcinoma
UA115517C2 (en) * 2010-02-08 2017-11-27 Ейдженсіс, Інк. Antibody drug conjugates (adc) that bind to 161p2f10b proteins
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
EP2550000A4 (en) 2010-03-24 2014-03-26 Advirna Inc Reduced size self-delivering rnai compounds
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
EP2796563A1 (en) 2010-05-04 2014-10-29 MedImmune, LLC Optimized degenerative muscle disease diagnostics and treatments
EP3091028A1 (en) 2010-05-26 2016-11-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
BR112012032462A2 (en) 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd antitumor agent employing compounds which, in combination, have kinase inhibiting effect.
KR102007045B1 (en) * 2010-07-07 2019-08-05 티유비아이티에이케이 Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2(vegfr-2/kdr)
CN101942022B (en) * 2010-07-29 2013-07-24 华东理工大学 Anti-human epidermal growth factor receptor single-chain antibody-ferritin heavy chain subunit protein and construction method and application thereof
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012112443A2 (en) 2011-02-15 2012-08-23 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
EP2697394A4 (en) 2011-04-12 2015-01-14 Electronic Biosciences Inc Site specific chemically modified nanopore devices
CN103402519B (en) 2011-04-18 2015-11-25 卫材R&D管理有限公司 tumor therapeutic agent
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
ES2705950T3 (en) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds
CA2840143A1 (en) * 2011-06-30 2013-01-03 Gene Signal International Sa Composition comprising inhibitors of irs-1 and of vegf
EP2540828A1 (en) 2011-06-30 2013-01-02 Gene Signal International SA Composition comprising inhibitors of IRS-1 and of VEGF
US9682144B2 (en) 2011-06-30 2017-06-20 Gene Signal International, Sa Composition comprising inhibitors of IRS-1 and of VEGF
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
HUE061002T2 (en) 2011-09-23 2023-04-28 Mereo Biopharma 5 Inc Vegf/dll4 binding agents and uses thereof
CN102492038B (en) * 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 Anti-human Tim-3 neutralized monoclonal antibody L3D and application thereof
RS61161B1 (en) 2011-12-13 2021-01-29 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
JP6348848B2 (en) 2012-02-13 2018-06-27 ガミダ セル リミテッド Proliferation of mesenchymal stem cells
EP2817028A4 (en) 2012-02-22 2015-11-04 Alethia Biotherapeutics Inc Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
WO2013134431A1 (en) 2012-03-06 2013-09-12 Life Technologies Corporation Biomarkers for systemic lupus erythematosus
EP2830663B1 (en) 2012-03-30 2019-02-06 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
US20150204873A1 (en) 2012-06-18 2015-07-23 Electonic Biosciences, Inc. Cell-free assay device and methods of use
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (en) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv Sulfonylation process using nonafluorobutanesulfonyl fluoride
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
CA2874864C (en) 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
JP6371294B2 (en) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods and monitoring of treatment with DLL4 antagonists
ES2701076T3 (en) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Hydrophilic linkers and their uses for the conjugation of drugs to molecules that bind to cells
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
HUE057977T2 (en) 2012-12-13 2022-06-28 Immunomedics Inc Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
JP6526570B2 (en) 2013-01-11 2019-06-12 マサチューセッツ アイ アンド イヤー インファーマリー CYP450 lipid metabolites that reduce inflammation and angiogenesis
AU2014218318B2 (en) 2013-02-18 2018-02-15 Vegenics Pty Limited Ligand binding molecules and uses thereof
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
KR102049990B1 (en) 2013-03-28 2019-12-03 삼성전자주식회사 Fusion protein comprising anti-c-Met antibody and VEGF binding fragment
US9452228B2 (en) 2013-04-01 2016-09-27 Immunomedics, Inc. Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
US10274503B2 (en) 2013-05-08 2019-04-30 Vegenics Pty Limited Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
CN105264380B (en) 2013-05-14 2017-09-05 卫材R&D管理有限公司 Pleasure is cut down for the biological marker of Buddhist nun's compound response for predicting and evaluating carcinoma of endometrium subject
KR101541478B1 (en) * 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 Anti-vegf antibodies and pharmaceutical composition comprising same for preventing, diagnosing or treating cancer or angiogenesis-related disease
EP3019243A4 (en) 2013-07-12 2017-03-15 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
EP4036118A1 (en) 2013-08-01 2022-08-03 Five Prime Therapeutics, Inc. Afucosylated anti-fgfr2iiib antibodies
US10934550B2 (en) 2013-12-02 2021-03-02 Phio Pharmaceuticals Corp. Immunotherapy of cancer
US9914769B2 (en) * 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
MX2016010683A (en) 2014-02-21 2017-05-11 Ibc Pharmaceuticals Inc Disease therapy by inducing immune response to trop-2 expressing cells.
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
EP3122757B1 (en) 2014-02-28 2023-09-06 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
IL275497B (en) 2014-03-20 2022-09-01 Bristol Myers Squibb Co Serum albumin-binding fibronectin type iii domains
WO2015164541A1 (en) * 2014-04-22 2015-10-29 Presage Biosciences, Inc. Methods and devices for evaluating drug candidates
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
MX2017001980A (en) 2014-08-28 2017-05-04 Eisai R&D Man Co Ltd High-purity quinoline derivative and method for manufacturing same.
SI3262071T1 (en) 2014-09-23 2020-07-31 F. Hoffmann-La Roche Ag Method of using anti-cd79b immunoconjugates
PL3204018T3 (en) 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
DK3212233T3 (en) 2014-10-31 2020-07-27 Oncomed Pharm Inc COMBINATION THERAPY FOR TREATMENT OF DISEASE
TWI695837B (en) 2014-12-04 2020-06-11 比利時商健生藥品公司 A triazolopyridazine as a kinase modulator
WO2016109943A1 (en) * 2015-01-06 2016-07-14 珠海亿胜生物制药有限公司 Anti-vegf antibody
AR103477A1 (en) 2015-01-28 2017-05-10 Lilly Co Eli VEGFA / ANG2 COMPOUNDS
BR112017017428A2 (en) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. " method for suppressing the bitterness of quinoline derivative "
CN107530291A (en) 2015-03-03 2018-01-02 奎尔波特股份有限公司 Double heavy duty liposomal pharmaceutical preparations
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
KR20170122809A (en) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 A combination of a PD-1 antagonist and a VEGFR / FGFR / RET tyrosine kinase inhibitor to treat cancer
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
KR20180018695A (en) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 Anticancer drug
ES2953441T3 (en) 2015-06-25 2023-11-13 Immunomedics Inc Combination of anti-hla-dr or anti-Trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3319936A4 (en) 2015-07-12 2019-02-06 Suzhou M-conj Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
SG10201913625XA (en) 2015-08-07 2020-03-30 Imaginab Inc Antigen binding constructs to target molecules
CA2999160A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
CN116987187A (en) 2015-09-23 2023-11-03 豪夫迈·罗氏有限公司 Optimized variants of anti-VEGF antibodies
WO2017053617A1 (en) 2015-09-23 2017-03-30 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
AU2016343860A1 (en) * 2015-10-30 2018-05-10 The Jackson Laboratory Compositions and methods relating to tumor analysis
RU2021107536A (en) 2015-11-23 2021-07-02 Файв Прайм Терапьютикс, Инк. FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN THE TREATMENT OF CANCER
AU2016364817B2 (en) 2015-12-03 2020-05-07 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP6910963B2 (en) 2016-01-06 2021-07-28 株式会社オーダーメードメディカルリサーチ High affinity anti-VEGF antibody
CN108779172B (en) * 2016-01-06 2022-02-08 定制药品研究株式会社 Antibodies that inhibit VEGF binding to NRP1
BR112018073133A2 (en) * 2016-05-10 2019-04-30 Genentech Inc methods of decreasing trisulfide bonds during recombinant polypeptide production
EP3467498A4 (en) * 2016-05-30 2019-11-13 Eiken Kagaku Kabushiki Kaisha Anti-human hemoglobin monoclonal antibody or antibody kit, insoluble carrier particle to which anti-human hemoglobin monoclonal antibody is immobilized, and measurement reagent and measurement method using same
GB2551979A (en) 2016-06-30 2018-01-10 Rs Arastirma Egitim Danismanlik Llac Sanayi Ticaret Ltd Cleavable polymer drug conjugates
US20190204326A1 (en) * 2016-09-27 2019-07-04 The University Of The Highlands And Islands Antigen biomarkers
RU2019114205A (en) * 2016-10-14 2020-11-16 Новартис Аг METHODS FOR TREATING EYE DISEASES USING CSF-1R INHIBITORS
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR20220147721A (en) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
GB2556055B (en) 2016-11-16 2022-03-23 Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Ltd Sti Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
EP3606963B1 (en) 2017-04-03 2023-08-30 F. Hoffmann-La Roche AG Antibodies binding to steap-1
BR112019022643A2 (en) 2017-05-02 2020-05-19 Nat Cancer Center Japan plasmin cleavable insoluble anti-fibrin antibody-conjugate
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
US10543231B2 (en) 2017-05-19 2020-01-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US10894019B2 (en) 2017-08-15 2021-01-19 University Of South Carolina Drug delivery system and method for targeting cancer stem cells
JP7436365B2 (en) * 2017-12-29 2024-02-21 エフ． ホフマン－ラ ロシュ アーゲー Anti-VEGF antibodies and methods of use
CN112055718A (en) * 2018-03-19 2020-12-08 药物抗体公司 anti-VEGFR-2 antibodies
WO2019211492A1 (en) 2018-05-04 2019-11-07 Tollys Tlr3 ligands that activate both epithelial and myeloid cells
US11672767B2 (en) 2019-05-13 2023-06-13 University Of South Carolina Enzymatically cleavable self-assembled nanoparticles for morphogen delivery
EP4021894A1 (en) 2019-08-30 2022-07-06 University of Rochester Septin inhibitors for treatment of cancers
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Methods of treating an eye disorder
TW202138388A (en) 2019-12-30 2021-10-16 美商西根公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
JPWO2022239720A1 (en) 2021-05-10 2022-11-17

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US4925922A (en) 1983-02-22 1990-05-15 Xoma Corporation Potentiation of cytotoxic conjugates
FR2566271B1 (en) 1984-06-20 1986-11-07 Sanofi Sa NOVEL CYTOTOXIC CONJUGATES FOR USE IN THERAPEUTICS AND PROCESS FOR OBTAINING SAME
CA1289880C (en) 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
FR2601679B1 (en) 1986-07-15 1990-05-25 Sanofi Sa IMMUNOTOXINS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
CA1338645C (en) 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5008196A (en) 1987-08-21 1991-04-16 Monsanto Company Stimulation of endothelial cell growth
US5036003A (en) 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5024834A (en) 1988-07-12 1991-06-18 Cetus Corporation Thioether linked immunotoxin conjugates
US6007817A (en) 1988-10-11 1999-12-28 University Of Southern California Vasopermeability enhancing immunoconjugates
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4940726A (en) 1989-04-26 1990-07-10 Arizona Board Of Regents Cell growth inhibitory macrocyclic lactones denominated Combretastatin D-1 and Combretastatin D-2
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5165923A (en) 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
DE69232718T2 (en) 1991-02-22 2003-04-03 American Cyanamid Co Identification of a human receptor tyrosine kinase gene
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20020032313A1 (en) 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
AU2861692A (en) 1991-10-18 1993-05-21 Beth Israel Hospital Association, The Vascular permeability factor targeted compounds
US6022541A (en) 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
US5234955A (en) 1991-12-20 1993-08-10 Eli Lilly And Company Antitumor compositions and methods of treatment
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
ATE239506T1 (en) 1992-03-05 2003-05-15 Univ Texas USE OF IMMUNOCONJUGATES FOR THE DIAGNOSIS AND/OR THERAPY OF VASCULARIZED TUMORS
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5281700A (en) 1992-08-11 1994-01-25 The Regents Of The University Of California Method of recovering endothelial membrane from tissue and applications thereof
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
AU673865B2 (en) 1992-10-29 1996-11-28 Australian National University, The Angiogenesis inhibitory antibodies
CN1173991C (en) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 Fik-1 as receiptor of growth factor of blood vessel inner-skin
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5879672A (en) 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
US5840301A (en) 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
GB9410533D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
EP0771216B9 (en) 1994-07-11 2003-01-02 The Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of tumoral vasculature
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
JPH09124697A (en) 1995-11-01 1997-05-13 Toagosei Co Ltd Peptide and monoclonal antibody
US5942385A (en) 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
US5851797A (en) 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
US6008319A (en) 1996-12-23 1999-12-28 University Of Southern California Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
US6291667B1 (en) 1997-01-31 2001-09-18 Parkash S. Gill Method and composition for treatment of kaposi's sarcoma
EP1787999B1 (en) 1997-04-07 2010-08-04 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DK0971959T3 (en) 1997-04-07 2006-05-15 Genentech Inc Humanized antibodies and methods for producing humanized antibodies
ATE312935T1 (en) * 1997-06-03 2005-12-15 REGULATORY SEQUENCES FOR IN VIVO EXPRESSION OF A HETEROLOGUE DNA SEQUENCE IN ENDOTHELIAL CELLS AND THEIR USES.
US6057435A (en) 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU2299099A (en) 1998-02-04 1999-08-23 Kyowa Hakko Kogyo Co. Ltd. Antibodies against human vegf receptor kdr
WO2000034337A1 (en) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
WO2000037502A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
ES2223705T3 (en) 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER THROUGH INHIBITION SELECTIVE OF VEGF.
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
NZ530582A (en) 2001-07-17 2008-06-30 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins, including granzyme, bax and TNF

Also Published As

Publication number Publication date
NZ514918A (en) 2003-11-28
US6887468B1 (en) 2005-05-03
KR100816572B1 (en) 2008-03-24
HK1045700A1 (en) 2002-12-06
US6342221B1 (en) 2002-01-29
US6676941B2 (en) 2004-01-13
KR20020019905A (en) 2002-03-13
ATE269357T1 (en) 2004-07-15
CA2372053C (en) 2008-09-02
CN101073668A (en) 2007-11-21
EP1185559A2 (en) 2002-03-13
MXPA01010891A (en) 2002-11-07
ZA200108612B (en) 2002-06-07
US20020119153A1 (en) 2002-08-29
AU763954B2 (en) 2003-08-07
WO2000064946A2 (en) 2000-11-02
IL145941A0 (en) 2002-07-25
IL145941A (en) 2007-08-19
US6342219B1 (en) 2002-01-29
JP2011046720A (en) 2011-03-10
DE60011612D1 (en) 2004-07-22
CN1308347C (en) 2007-04-04
JP2002543093A (en) 2002-12-17
EP1179541A1 (en) 2002-02-13
ES2223705T3 (en) 2005-03-01
CN1358197A (en) 2002-07-10
EP1179541B1 (en) 2004-06-16
BR0010017A (en) 2002-06-11
ZA200108285B (en) 2002-08-28
US7056509B2 (en) 2006-06-06
US6524583B1 (en) 2003-02-25
US20030175276A1 (en) 2003-09-18
HK1045700B (en) 2007-07-27
JP4926320B2 (en) 2012-05-09
WO2000064946A3 (en) 2001-02-15
US6416758B1 (en) 2002-07-09
AU4804900A (en) 2000-11-10
DE60011612T2 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
CA2372053A1 (en) Compositions and methods for cancer treatment by selectively inhibiting vegf
MX2010005104A (en) Anti-vegf antibody compositions and methods.
WO1999063930A3 (en) Novel angiotensin receptor modulators and their uses
PT1187918E (en) TEK ANTAGONISTS
WO2002002638A3 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
SI2269656T1 (en) Selected antibodies binding to aminophospholipids and their use in treatment, such as cancer
HK1061199A1 (en) Pharmaceutical compositions comprising arsenic trioxide for the treatment of multiple myeloma
WO2006015060A3 (en) Isoindoline compounds and methods of their use
WO2001060806A3 (en) Substituted arylpyrazines
MX2010003325A (en) Novel antibodies.
WO2003061559A3 (en) Binding peptides specific for the extracellular domain of erbb2 and uses therefor
WO2002077172A3 (en) Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
WO2002020768A3 (en) Caveolin peptides and their use as therapeutics
WO2000018439A3 (en) Use of neoangiogenesis markers for diagnosing and treating tumours by therapy
DK1079851T3 (en) Use of anti-prolactin agents for the treatment of cancer
DK1107795T3 (en) Thiomolybdate associated with at least one carbohydrate and its use in the prevention or treatment of diseases characterized by aberrant vascularization such as cancer, wet type macular degeneration, rheumatoid arthritis
WO2002022166A3 (en) Tweak receptor agonists as anti-angiogenic agents
WO1999064050A8 (en) Novel potassium channel drugs and their uses
EP1234585A3 (en) Methods and compositions for the prevention or treatment of cancer
WO2002043776A3 (en) Neuropeptide y1 receptor binding compounds in the treatment and diagnosis of cancer
EP1027890A3 (en) Homer a new target of treating psychiatric disorders

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190429